Literature DB >> 1539462

Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit.

S Gizurarson1, S Tamura, C Aizawa, T Kurata.   

Abstract

Secretory antibodies in mucosal surfaces are known to play an essential role in protection against various infectious diseases. To enhance the production of such antibodies, influenza HA vaccine was inoculated intranasally into rabbits, together with cholera toxin B subunit (CTB) which is known to augment antibody response to an unrelated antigen. This combination resulted in high levels of serum IgG antibody responses against HA and CTB molecules, 3-4 weeks after inoculation, compared with the inoculation of HA vaccine alone. The adjuvant mechanism for CTB was studied by using Ussing chambers, in which nasal mucosa from rabbits were mounted. CTB was found to enhance the transepithelial flux of HA vaccine, from the mucosal side (lumen) into the serosal side (lamina propria), indicating that the permeability of the membrane was changed by CTB. Moreover, to achieve effective flux of HA vaccines, some interactions between the vaccine and CTB across the membrane were found, which may effect the effectiveness of the vaccine formulation. The results suggest that one of the mechanisms by which CTB enhances the production of mucosal antibody response is to enhance the transepithelial influx of vaccine into the nasal mucosa, where the cells involved in the antibody production are located. CTB may be used as a potent adjuvant to induce antibody response, by nasal vaccination, against pathogens impinging on mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539462     DOI: 10.1016/0264-410x(92)90025-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

2.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Optimal delivery of vaccines: clinical pharmacokinetic considerations.

Authors:  S Gizurarson
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

4.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.

Authors:  H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

7.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; E Saeland; S Gizurarson; D Schulz; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.

Authors:  J Katz; C C Harmon; G P Buckner; G J Richardson; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.

Authors:  M Martin; D J Metzger; S M Michalek; T D Connell; M W Russell
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.